Medullary thyroid cancer (MTC) is a rare neuroendocrine tumor that has specific diagnostic and therapeutic requirements. Currently, imaging tools show great limits to localize all residual MTC foci. Non-invasive imaging is helpful but far from perfect for guiding the re-exploration for loco regional residual MTC. The therapeutic approach is different between sporadic and hereditary MTC. In order to obtain the biochemical and anatomical control the first surgical resection is critical. Calcitonin (Ctn) rate used for MTC recurrence detection as serum marker is definite. Yet it poses a unique challenge notwithstanding its ability in detecting microscopic subclinical disease; it is not clear if patients with evident biological signs of residual MTC should be closely observed when MTC is finally found out through different investigations that localize it, or if a different aggressive approach is necessary including central neck dissection, whether or not associated with ipsilateral or bilateral lateral neck dissection. In all phases of the disease, the co-treatment by physicians with experience in MTC therapy should be sought.

Medullary thyroid cancer: strategy, pitfalls and technical aspects with emphasis on remedial surgery

Vincenzo Bartolo;Antonino Cancellieri;Antonina Catalfamo;Fausto Famà
;
Francesca Pia Pergolizzi;Gianlorenzo Dionigi
Ultimo
2018-01-01

Abstract

Medullary thyroid cancer (MTC) is a rare neuroendocrine tumor that has specific diagnostic and therapeutic requirements. Currently, imaging tools show great limits to localize all residual MTC foci. Non-invasive imaging is helpful but far from perfect for guiding the re-exploration for loco regional residual MTC. The therapeutic approach is different between sporadic and hereditary MTC. In order to obtain the biochemical and anatomical control the first surgical resection is critical. Calcitonin (Ctn) rate used for MTC recurrence detection as serum marker is definite. Yet it poses a unique challenge notwithstanding its ability in detecting microscopic subclinical disease; it is not clear if patients with evident biological signs of residual MTC should be closely observed when MTC is finally found out through different investigations that localize it, or if a different aggressive approach is necessary including central neck dissection, whether or not associated with ipsilateral or bilateral lateral neck dissection. In all phases of the disease, the co-treatment by physicians with experience in MTC therapy should be sought.
2018
File in questo prodotto:
File Dimensione Formato  
aot-03-8.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 757.26 kB
Formato Adobe PDF
757.26 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11570/3126005
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact